Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) traded down 4% on Wednesday . The company traded as low as $11.61 and last traded at $11.90. 13,428 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 221,583 shares. The stock had previously closed at $12.39.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the company. Leerink Partners assumed coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued an "outperform" rating and a $28.00 price objective on the stock. Leerink Partnrs upgraded Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. JPMorgan Chase & Co. initiated coverage on Maze Therapeutics in a report on Tuesday, February 25th. They set an "overweight" rating and a $30.00 price target on the stock. Finally, Guggenheim reiterated a "buy" rating and set a $19.00 price target on shares of Maze Therapeutics in a report on Wednesday, April 2nd. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $25.67.
Get Our Latest Stock Report on MAZE
Maze Therapeutics Price Performance
The firm has a fifty day simple moving average of $10.54.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
Institutional Trading of Maze Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of MAZE. New York State Common Retirement Fund purchased a new stake in Maze Therapeutics in the 1st quarter valued at about $25,000. Corebridge Financial Inc. purchased a new stake in Maze Therapeutics in the 1st quarter valued at about $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Maze Therapeutics in the 1st quarter valued at about $57,000. Rhumbline Advisers purchased a new stake in Maze Therapeutics in the 1st quarter valued at about $80,000. Finally, Deutsche Bank AG purchased a new stake in Maze Therapeutics in the 1st quarter valued at about $98,000.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Read More
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
